Stay updated on Seagen Press Releases
Sign up to get notified when there's something new on the Seagen Press Releases page.

Latest updates to the Seagen Press Releases page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA new Medicines and Prescription Medicines section is added to the Press Releases page, featuring a press release announcing FDA approval of PADCEV plus Keytruda for muscle-invasive bladder cancer (07.10.2026). The page also removes the Research and Research and Pipeline categories and a May 28, 2026 Pfizer and Innovent Biologics collaboration item, reflecting a reorganization toward medicines-focused content.SummaryDifference2%

- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedNew June 2026 press releases were added to the list, including the dividend announcement, investor webcast, and topline trial results, while several May 2026 items were removed, updating the newsroom's current headlines.SummaryDifference9%

- Check35 days agoChange DetectedThe page now adds a Leadership section with the Chief Financial Officer transition release (06.18.2026) and a Supplier & B2B Resources link. It also removes the ELREXFIO press release from April 2026 and its related category labels.SummaryDifference2%

- Check42 days agoChange DetectedA new HYMPAVZI press release appears under Medicines/Prescription Medicines dated 06.08.2026, and older Finance/Corporate categories and the VYNDAMAX settlement release (04.28.2026) are removed from the page.SummaryDifference2%

- Check49 days agoChange DetectedJune 2026 press releases were added to the Newsroom, including updates on Berobenatide Phase 2b, a webcast invitation, and a BRAFTOVI regimen update. Older April 2026 releases were removed.SummaryDifference10%

- Check56 days agoChange DetectedFour May 2026 press releases were added to the Newsroom, covering TALZENNA Plus XTANDI results in metastatic prostate cancer, LORBRENA CROWN trial results in advanced NSCLC, a global collaboration with Innovent Biologics to accelerate oncology medicines, and an investor webcast invitation.SummaryDifference8%

Stay in the know with updates to Seagen Press Releases
Enter your email address, and we'll notify you when there's something new on the Seagen Press Releases page.